News for Nektar Therapeutics (0UNL.L)

PR NewswireSAN FRANCISCO, July 2, 2025 SAN FRANCISCO, July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology compa

Market Analysis by covering: Nektar Therapeutics, Cidara Therapeutics Inc, GeneDx Holdings Corp. Read 's Market Analysis on Investing.com

Follow The Leaders - Here Are The 50 Strongest Stocks Of 2025. Here are the strongest stocks of 2025.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.

U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesday. Shares of AeroVironment, Inc. AVAV rose sharply during Wednesday's session a...

Republicans are reconsidering their stance on clean energy tax credits.

It's important to note that FedEx is in the process of spinning off its freight business...

Biogen said Wednesday its experimental treatment helped children with SMA even after they received an approved gene therapy from Novartis.

GeneDx stock jumped again Tuesday after the American Academy of Pediatrics green-lit genetic testing for a larger pool of children.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 1% on Tuesday. The Dow traded up 1.11% to 43,054.08 while the NASD...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Tuesday. Following the market opening Tuesday, the Dow traded up 0.62% to ...

Nektar Therapeutics' REZPEG shows progress in treating atopic dermatitis & alopecia areata. Click here to find out why I rate NKTR stock a Buy.

Trading for Nektar (NKTR) shares has been temporarily suspended as the market awaits a significant update. Investors are anticipating news that could impact the

PR NewswireSAN FRANCISCO, May 13, 2025 SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will

Nektar Therapeutics (NKTR) will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The presentation will be w

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nektar Therapeuti

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NNKTR.OQ - Nektar TherapeuticsQ1 2025 Nektar Therapeutics Earnings CallMay 08, 2025 / 09:00PM G